4.5 Article

A prospective survey of febrile events in hematological malignancies

期刊

ANNALS OF HEMATOLOGY
卷 91, 期 5, 页码 767-774

出版社

SPRINGER
DOI: 10.1007/s00277-011-1373-2

关键词

Epidemiology; Hematological malignancies; Febrile events; Registry

资金

  1. Merck Sharp Dohme, Italy
  2. MSD-Italy
  3. Pfizer
  4. Gilead
  5. Merck
  6. Cephalon
  7. Schering Ploug
  8. Roche
  9. Genzyme
  10. Celgene
  11. Shire
  12. Astellas

向作者/读者索取更多资源

The Hema e-Chart prospectively collected data on febrile events (FEs) in hematological malignancy patients (HMs). The aim of the study was to assess the number, causes and outcome of HM-related FEs. Data were collected in a computerized registry that systematically approached the study and the evolution of FEs developing in a cohort of adult HMs who were admitted to 19 hematology departments in Italy from March 2007 to December 2008. A total of 869 FEs in 3,197 patients with newly diagnosed HMs were recorded. Fever of unidentified origin (FUO) was observed in 386 cases (44.4%). The other causes of FE were identified as noninfectious in 48 cases (5.5%) and infectious in 435 cases (50.1%). Bacteria were the most common cause of infectious FEs (301 cases), followed by fungi (95 cases), and viruses (7 cases). Mixed agents were isolated in 32 episodes. The attributable mortality rate was 6.7% (58 FEs). No deaths were observed in viral infection or in the noninfectious groups, while 25 deaths were due to FUO, 16 to bacterial infections, 14 to fungal infections, and three to mixed infections. The Hema e-Chart provided a complete system for the epidemiological study of infectious complications in HMs.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.5
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据